Veriheal

SEPTEMBER 18, 2020

Conventional forms of treatment are often accompanied by adverse side effects but there is hope for effective treatment with fewer side effects. . million of NWS Health funding for their Cannabinoid Therapeutics and Brain and Mind Centre to see if cannabidiol can be that effective treatment for spinal cord injury.

Treatment 98

Treatment Chronic Pain Research and Development CBD 98

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. For instance, as of June 2021, InMed Pharmaceuticals, Inc.,

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. USOTC: USMJ).

Treatment 52

Treatment Research and Development CBD eCommerce 52

TheAnswerPage

JULY 13, 2021

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Veriheal

MARCH 20, 2023

Using psilocybin in small doses, or microdosing, has been shown to aid in the treatment of various mental health issues, including anxiety, depression, PTSD, and obsessive-compulsive disorder. Smith cited results from clinical trials showing that MDMA holds promise in the treatment of PTSD. Connecticut Gov. Minnesota Rep.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF ), ( Bionomics ) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares ( ADSs ) in the United States and a concurrent listing of ADSs on Nasdaq.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. RADNOR, Pa.–(BUSINESS Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. What’s more, over the coming years psychedelics will continue to gain acceptance for treating these conditions which will also contribute to that market growth.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Veriheal

MAY 25, 2023

This powerful anesthetic may offer swift symptomatic relief from the symptoms of widespread mental health conditions, including anxiety, bipolar disorder, treatment-resistant depression /major depression, PTSD (post- traumatic stress disorder), OCD ( obsessive-compulsive disorder), and various addictions/substance use disorders.

Medicine 98

Medicine Blood Pressure Therapy Clinical Trials 98

Cannabis Law Report

MAY 28, 2022

We lateraled to Husch Blackwell together in April 2021 as part of a larger team. We have been following the research and development of these medicines for psychiatric conditions such as PTSD and treatment-resistant depression. How did this come to fruition? Read full article at.

Research and Development 52

Research and Development Therapy Clinical Trials Legalization 52

Cannabis Law Report

DECEMBER 1, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Date: December 2, 2021. Dates: December 8-9, 2021. Registration: Click here.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. Queensland was the source of 51% of prescriptions between 2016 and 2021. We are aware of clinical trials in that space, but not strong evidence.”. Read their full article at.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. During the six months ended September 30, 2021, the Company raised approximately $4.1 million for the three months ended September 30, 2021, from approximately $1.48

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

The Cannigma

MARCH 7, 2022

CBN’s ability to target CB2 receptors, in comparison to THC (which prefers the CB1 receptor), gives it better credibility in treating autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. What can the current clinical trials tell us? Common cannabinoids in cannabis.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

AUGUST 17, 2021

Therapeutic Medical Devices are Preferred by Physicians and Patients for Acute and Chronic Respiratory Conditions. Most of the Mobile Medical Applications in Clinical Trials are Monitoring Symptoms that can Support Early Disease Diagnosis. Smart Inhalers Enable High Patient Engagement and Improve Treatment Effectiveness.

Research and Development 98

Research and Development Clinical Trials Concentrates Patients 98

Cannabis Law Report

JANUARY 12, 2022

. “Gb Sciences has established a pipeline of patent-protected combination therapies for the treatment of medical conditions affecting hundreds of millions of people,” said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. In addition, Gb Sciences has 12 U.S.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

OCTOBER 13, 2021

The PCT filing also includes support for future research programs respecting various systems which seek to minimize negative side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. US Provisional Patent Filed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

OCTOBER 9, 2021

A coalition of Pennsylvania lawmakers introduced a bill this week that’s meant to promote research into the therapeutic potential of psilocybin mushrooms for mental health conditions such as post-traumatic stress disorder (PTSD)—the latest example of how the psychedelics reform movement is gaining momentum. Posted: July 26, 2021 12:18 PM.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

AUGUST 3, 2021

The Shares were offered in each of the provinces of Canada, excluding Québec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. Vigorous scientific research and clinical trials are needed.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

SpeedWeed

SEPTEMBER 17, 2021

The funding will allow MAPS Public Benefit Corporation (MAPS PBC) to activate a team to evaluate the scope of the lack of resources needed for TBI treatment. . Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

NOVEMBER 25, 2021

Epilepsy Treatment. The Food and Drug Administration (FDA) recently approved the use of CBD to help treat the condition in individuals as young as two years old. Depression and anxiety are serious mental health conditions that should be taken seriously. Thus far, few indications of negative side effects have been found.

CBD 52

CBD Clinical Trials Epilepsy Chronic Pain 52

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. March 8, 2021). Id ; 21 CFR 312.1-10; 10; 312.80-88; 88; 312.300 et seq. 360bbb-0a(a)(2).

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

JULY 29, 2021

VANCOUVER, BC , July 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: of their dry weight and it is not practical to obtain meaningful pure amounts of these compounds from the flesh of mushrooms, at a reasonable cost, to conduct clinical trials in humans and to commercialize these products. On Behalf of the Board.

Clinical Trials 105

Clinical Trials Conditions Packaging Events 105

Cannabis Law Report

NOVEMBER 19, 2021

19, 2021 /CNW/ – PsyBio Therapeutics Corp. “These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

DECEMBER 21, 2021

This UK-based company caught our attention in 2021 for its team of renowned psychedelic researchers, including chief research officer Professor David Nutt, chief medical officer Dr. Ben Sessa, and head of ketamine psychotherapy Dr. Celia Morgan, as well as its unique studies into ketamine treatment for addiction and gambling addiction.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

SpeedWeed

AUGUST 11, 2021

Suicide among veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for pain, depression, and PTSD,” said Sisley in a press statement. The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In May 2021, a Nature Medicine study showed the benefits of MDMA in relieving post-traumatic stress disorder. [4] 5] The Journal of the American Medical Association published similar findings in May 2021. [6].

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

JUNE 8, 2021

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. About Silo Pharma.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., at the end of the 17 weeks of ganaxolone treatment.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

SpeedWeed

SEPTEMBER 4, 2021

Titled “Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021,” the article specifically includes some major changes for cannabis and psilocybin. Some states in the U.S.

DEA 52

DEA Research and Development Clinical Trials Extraction 52

Cannabis Law Report

AUGUST 24, 2021

. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D., President, Director and Chief Medical Officer.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

FEBRUARY 3, 2022

million in 2021, and is projected to reach USD 176,005.5 million by 2030 at a CAGR of 23.9%, 2021-2030. Inhalation is considered to be the fastest and popular method for treating medical conditions and recreation activities. Growing Adoption of Medical Cannabis for the Treatment of Chronic Compounds. 2564 (2021).

Indica 52

Indica Oil Legalization Research and Development 52

Canna Care Docs

DECEMBER 16, 2020

It would feel like an out-of-body experience, except for one fact: your body is constantly reminding you of those symptoms you’ve been suffering from all this time, putting treatment on the back burner while you deal with life as we know it. What conditions is medical marijuana helpful for? Enough is enough. What is medical marijuana?

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52